The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Zolbetuximab & chemotherapy in claudin 18.2+ metastatic pancreatic cancer
Teresa Macarulla, MD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses results from the Phase II GLEAM study (NCT03816163) of zolbetuximab with gemcitabine and nab-paclitaxel versus chemotherapy alone in previously untreated claudin 18.2-positive metastatic pancreatic adenocarcinoma (PAC). Overall survival was similar between arms, though exploratory biomarker analysis suggested patients with elevated interleukin-18 levels may derive greater benefit from zolbetuximab. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
